NeoGenomics, Inc. (NEO): Price and Financial Metrics

NeoGenomics, Inc. (NEO): $14.24

0.35 (+2.52%)

POWR Rating

Component Grades








NEO Price/Volume Stats

Current price $14.24 52-week high $21.22
Prev. close $13.89 52-week low $11.03
Day low $13.90 Volume 519,454
Day high $14.33 Avg. volume 879,511
50-day MA $14.72 Dividend yield N/A
200-day MA $15.23 Market Cap 1.82B

NEO Stock Price Chart Interactive Chart >

NeoGenomics, Inc. (NEO) Company Bio

NeoGenomics, Inc. operates a network of cancer-focused testing laboratories providing genetic and molecular testing services to hospitals, pathologists, oncologists, urologists, other clinicians and researchers, and other laboratories in the United States. The company was founded in 2001 and is based in Fort Myers, Florida.

NEO Latest News Stream

Event/Time News Detail
Loading, please wait...

NEO Latest Social Stream

Loading social stream, please wait...

View Full NEO Social Stream

Latest NEO News From Around the Web

Below are the latest news stories about NEOGENOMICS INC that investors may wish to consider to help them evaluate NEO as an investment opportunity.

S&P 500 Misses Out On Record As Stock Market Fades Late; Small Caps On Pace For Record December

The S&P 500 came within inches of a record high Thursday, but had to settle for a minute gain as the stock market faded and small caps broke a trend of outperformance. The S&P 500 climbed less than 0.1%. The Nasdaq composite closed fractionally lower after erasing modest gains.

Yahoo | December 28, 2023

NeoGenomics to Appeal Ruling

FORT MYERS, FL / ACCESSWIRE / December 28, 2023 / NeoGenomics, Inc. (NASDAQ:NEO) (the "Company"), a leading oncology testing services company, today announced that NeoGenomics Laboratories, Inc., a subsidiary of NeoGenomics Inc., will appeal the preliminary ...

Yahoo | December 28, 2023

NeoGenomics to Present New Data at San Antonio Breast Cancer Symposium Highlighting Utility of RaDaR for Therapy Response

FT. MYERS, FL / ACCESSWIRE / December 5, 2023 / NeoGenomics, Inc. (NASDAQ:NEO), a leading oncology testing services company, today announced new data highlighting its RaDaR® assay for minimal residual disease (MRD) will be presented at the 46th annual ...

Yahoo | December 5, 2023

NeoGenomics to Participate at the Piper Sandler 35th Annual Healthcare Conference

FT. MYERS, FL / ACCESSWIRE / November 14, 2023 / NeoGenomics, Inc. (NASDAQ:NEO), a leading oncology testing services company, today announced the company will participate in the upcoming Piper Sandler 35th Annual Global Healthcare Conference in New ...

Yahoo | November 14, 2023

Wall Street Analysts See a 28.17% Upside in NeoGenomics (NEO): Can the Stock Really Move This High?

The average of price targets set by Wall Street analysts indicates a potential upside of 28.2% in NeoGenomics (NEO). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Yahoo | November 13, 2023

Read More 'NEO' Stories Here

NEO Price Returns

1-mo 1.50%
3-mo -15.19%
6-mo -26.14%
1-year -18.02%
3-year -63.65%
5-year -32.99%
YTD -11.99%
2023 75.11%
2022 -72.92%
2021 -36.63%
2020 84.07%
2019 131.96%

Continue Researching NEO

Here are a few links from around the web to help you further your research on Neogenomics Inc's stock as an investment opportunity:

Neogenomics Inc (NEO) Stock Price | Nasdaq
Neogenomics Inc (NEO) Stock Quote, History and News - Yahoo Finance
Neogenomics Inc (NEO) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!